Detecting protein-RNA interactions is challenging both experimentally and computationally because RNAs are large in number, diverse in cellular location and function, and flexible in structure. As a result, many RNA-binding proteins (RBPs) remain to be identified. Here, a template-based, function-prediction technique SPOT-Seq for RBPs is applied to human proteome and its result is validated by a recent proteomic experimental discovery of 860 mRNA-binding proteins (mRBPs). The coverage (or sensitivity) is 42.6% for 1217 known RBPs annotated in the Gene Ontology and 43.6% for 860 newly discovered human mRBPs. Consistent sensitivity indicates the robust performance of SPOT-Seq for predicting RBPs. More importantly, SPOT-Seq detects 2418 novel RBPs in human proteome, 291 of which were validated by the newly discovered mRBP set. Among 291 validated novel RBPs, 61 are not homologous to any known RBPs. Successful validation of predicted novel RBPs permits us to further analysis of their phenotypic roles in disease pathways. The dataset of 2418 predicted novel RBPs along with confidence levels and complex structures is available at http://sparks-lab.org (in publications) for experimental confirmations and hypothesis generation.
INTRODUCTION
A comprehensive understanding of cellular processes requires identification of RNA-binding proteins (RBP) as well as their ligands. Identification of RBPs is of significant interest because numerous studies have shown that they are key factors associated with cellular processes such as cell cycle checkpoints and genomic stability, and mutations in RBPs are linked to human diseases, including cancer. 1 Recent global analysis indicates that transcripts are not only large in number but also diverse in localization and function in cells. [2] [3] [4] This implies that underlying post-transcriptional networks are likely larger and more complex than either transcriptional networks or protein-protein interaction networks. 5 However, experimental determination of RNA-binding by every protein is inefficient and impractical, as well as technically challenging and expensive. Attempts at highthroughput biochemical approaches for identifying RBPs progress slowly and are fraught with inaccuracy. 5-7 Thus, computational methods have become a critical component for function annotation and analysis of RBPs. [8] [9] [10] [11] [12] [13] [14] [15] [16] Recently, we have developed a template-based technique called SPOT-Seq (RNA) that makes sequencebased prediction of RBPs. 16 In this method, a query sequence is first threaded onto protein template structures of protein-RNA complexes by the fold recognition technique called SPARKS X. 17 The template library contains 1164 known protein-RNA complex structures on both domain and protein chain levels (95% sequence identity or less). If one of the templates has a good match (according to Z-score) to the query, the structure for the query is predicted and a model complex structure between the predicted structure and the RNA from the template is built. The model complex structure is then used to predict affinity for protein-RNA-binding using a knowledge-based energy function. 15 If the binding affinity is higher than a threshold, an RBP is predicted. The method achieves a precision of 84% and sensitivity of 47% for a test set of 215 RBPs and 5765 nonbinding proteins. The precision and sensitivity of SPOT-Seq are more than 10% higher than PSI-BLAST, which uses a sequence-to-profile homology search technique. 18 More importantly, unlike some computational methods, SPOT-Seq (RNA) can distinguish DNA-binding from RNA binding (zero false positives) when applied to 250 DNA binding proteins.
Here, we made a large-scale prediction of RBPs in human proteome using SPOT-Seq and recovered 42.6% for annotated RBPs in human proteome. These predictions, when compared with recently discovered 860 messenger RNA binding proteins in human HeLa cells, 19 yielded a consistent sensitivity of 43.6%. More than 2000 novel RBPs are predicted in which 291 proteins are validated by the recently discovered messenger RNA binding proteins. We further showed that some of these novel RBPs are involved in various disease pathways.
MATERIALS AND METHODS

Fold-recognition and binding-affinity based prediction by SPOT-Seq
SPOT-Seq combines fold recognition and binding affinity prediction for RBP prediction. 16 Each target sequence is aligned to the structures in a template library of 1164 nonredundant protein-RNA complex structures (95% sequence identity cutoff) by using the fold recognition method SPARKS X. 17 If the Z-score of the fold recognition is greater than 8.04, a model complex structure between the target protein and template RNA is built by replacing template protein sequence with target protein sequence based on the sequence-to-structure alignment generated from SPARKS X. The model complex structure is then used to estimate binding affinity according to a statistical energy function based on the distance-scaled finite ideal-gas reference state 20 that was extended to protein-RNA interaction (DRNA). 15 If the predicted threshold is lower than 20.57, the target protein is predicted as RNA-binding and its complex structure model serves as the basis for the high-resolution prediction of RNA-binding function. The energy and Z-score thresholds (20.57 and 8.04, respectively) were obtained by optimizing the Matthews correlation coefficient (MCC) based on the leave-homolog-out cross validation with a dataset of 216 RBPs and 5765 non-RBPs. 16 We chose to optimize MCC values because MCC is a balanced measure of sensitivity and precision for a training database with an unbalanced number of RNA-binding and nonbinding proteins.
RESULTS
Application of SPOT-Seq to human proteome
The human genome dataset from the Uniprot database contains 20,270 unique proteins. 21 The annotations of these genes were obtained from the Gene Ontology (GO) database. 22 We defined an RBP as one whose annotation contains any of the keywords ("RNA binding," "ribosomal," "ribonuclease," or "ribonucleoprotein"). For proteins with keywords "RNA polymerase," we limited to 17 specific GO terms as RBPs (see Table I ). This definition leads to 1217 (6%) proteins annotated as RBPs, whereas 15,595 proteins are annotated with other functions and 3458 are unannotated (unknown function). Table I lists the number of proteins found according to the keywords used. Although this definition of RBP is subject to annotation errors/omissions and choices of keywords, it provides a useful reference for analyzing our predicted RBPs.
Application of SPOT-Seq to human proteome identified 2937 proteins as RNA-binding after removing those proteins whose predicted structures have overlap with RNA-Binding Proteins in Human Proteome predicted transmembrane regions by THUMBUP. 23 This filter is necessary because our method based on protein-RNA complex structures cannot predict the structures of transmembrane proteins. Among 2937 predicted RBPs, 519 proteins were annotated as RNA-binding and belong to one of the keyword classes shown in Table I . In addition, 1848 proteins were annotated with functions other than RNA-binding and 570 proteins lack annotations. Figure 1 shows a bar diagram that indicates the number of predicted RBPs in annotated RBPs, non-RBPs annotated with other function, and proteins with unknown function. The result reveals sensitivity (or coverage) of 42.6% (519/1217). This sensitivity is consistent with results from our benchmark study 16 despite the latter being based on proteins whose structures were solved in complex with RNA. We noted that the sensitivity strongly depends on specific categories of RBPs. The sensitivity is the highest at 56% for the proteins annotated with the keyword of "RNA binding" and the lowest at 13% with the keyword of "RNA polymerase" as shown in Table I . Table II lists the top 10 templates used for all predicted RBPs for human proteome. The 60S ribosomal protein L3 encoded by the RPL3 gene (chain C in PDB structure 3o58) is responsible for predicting 1181 proteins with 61 annotated as RNA binding. Four other 60S ribosomal proteins are also in the top-10 list. The unexpected popularity of L3 as a template leads us to examine the accuracy associated with these predictions. SPOTseq was tested by 215 RBPs and 5765 non-RBPs. 16 Among these proteins, 11 binding proteins and 15 nonbinding targets used protein chains contained in structure 3o58 as templates. The MCC for the use of 3o58 chains as templates is 0.64, similar to the overall MCC value of 0.62 when all templates are used. Thus, the performance for prediction based on 3o58 chains is consistent with the overall performance.
Newly predicted human RBPs have the same non-RNA-binding functions as known RBPs A total of 1848 predicted novel RBPs were annotated with functions other than RNA-binding. That is, these proteins perform a moonlighting role of RNA-binding. We investigated novel and existing moonlighting RBPs based on their shared molecular functions. In Table III , we tabulate number of proteins and GO terms in molecular function that are unique or shared between predicted and annotated RBPs. More than 90% of predicted novel RBPs [91%, 226/(226 1 21) for proteins with root annotations only and 98%, 1238/(1238 1 26) for proteins with leaf annotations] shared GO IDs with annotated RBPs. In other words, almost all functions of these predicted moonlighting RBPs are associated with known RBPs. We noted that the entire human proteome has 1411 leaf GO IDs and annotated RBPs have 288 leaf GO IDs. That is, 20% of all leaf GO IDs associated with The last letter in PDB ID is the chain ID. # Nonredudant is the number of proteins that are 30% sequence identity or lower among each other.
RBPs indicate the extensive association of RBPs with other biological functions.
To illustrate shared functions between predicted and annotated RBPs, we showed four clusters of predicted and annotated RBPs with four GO IDs in Figure 2 . Each GO ID not only contains both predicted and annotated RBPs but also connects with each other through proteins having multiple GO IDs. Top 10 GO IDs (excluding RNA-binding functions) enriched with moonlighting RBPs are listed in Table IV . Many of these 10 GO IDs are associated with transcription regulatory activity, suggesting DNA-binding activity. For example, zinc-ion-binding has an odd ratio of 1.06 enriched with annotated RBPs (fraction of annotated RBPs in a given GO ID in all annotated RBPs vs. fraction of all proteins in a given GO ID in all proteins). This odd ratio increases to 1.82 with predicted novel RBPs. Indeed, we found that 350 out of 1217 annotated RBPs (29%) are also annotated as DNAbinding proteins according to GO annotations. Similarly, 22% (114/519) of predicted and annotated RBPs and 39% (728/1848) of predicted novel moonlighting RBPs are DNA-binding proteins. Thus, a significant fraction of proteins likely interact with DNA and RNA at the same time. It is worth to mention that SPOT-Seq has 100% success rate in discriminating RNA from DNA-binding proteins. 16
Validation of predicted novel RBPs by proteomic studies of human HeLa cells
Sharing GO IDs between annotated and predicted RBPs supports but does not validate predicted novel RBPs. Direct validation of our predicted RBPs is made possible by a recent proteomic experiment that detected mRNA-binding proteins (mRBPs) of HeLa cells. 19 In this study, mRBPs in living HeLa cells were crosslinked by UV irradiation, captured by oligo(dT) magnetic beads after cell lysis, and identified by high-resolution nano-LC-MS/MS. They identified 860 mRBPs in which 375 were predicted as RBPs by SPOT-Seq. That is, the sensitivity for this dataset is 43.6%, close to 42.6% sensitivity for all GO annotated RBPs. Similar sensitivity despite significantly different datasets confirms the overall accuracy of SPOT-Seq.
The 860 mRBPs contain many novel RBPs. Using the same GO definition for RBPs as in the human proteome, 746 proteins were novel RBPs in which 291 were predicted as RBPs by SPOT-Seq. Thus, SPOT-Seq has a 39% sensitivity for identification of novel RBPs, close to the sensitivity for all RBPs (42.6%). In these 291 predicted and validated mRBPs, the most frequently used templates were chains in PDB ID 3o58 (87 times). This validates the use of 3o58 as a template for predicting RBPs. Moreover, the majority of 291 predicted novel proteins (70%, 203/291) used a template protein with mRNA binding function. Annotated  1217  118  92  477  47  483  95  189  192  96  A-A\P  698  102  56  221  29  290  84  178  143  83  A\P  519  16  36  256  18  193  11  11  39  13  P-AOP  2418  907  21  226  26  1238  148  189 250 96 a A-A\P (annotated but not predicted RBPs), A\P (annotated and predicted RBPs), and P-A\P (predicted but not annotated as RBPs). b The total number of proteins, the number of proteins without GO IDs, with unique GO IDs, and shared GO IDs between predicted and annotated proteins at root and leaf levels. c The number of GO IDs that are unique or shared between predicted and annotated proteins at root and leaf levels.
Figure 2
The connection between proteins with four GO terms (GO:0030528, GO:0008270, GO:0001883, and GO:0000287, in yellow) that are shared by annotated but not predicted (Gray), predicted and annotated (Blue), and predicted and novel (Red) RBPs. Each node represents a protein.
One protein can connect to one or more GO terms. This diagram is to illustrate that predicted and annotated RBPs are associated with same non-RNA-binding functions.
Castello et al. 19 also defined a more stringent subset of "previously unknown" RBPs by excluding proteins that were previously experimentally validated, inferable by homology, and/or with a GO annotation containing "RNA" (not just RNA binding). This stringent set of "previously unknown" RBPs contains 315 proteins, 61 of which (19%) are predicted novel RBPs by SPOT-Seq. This large overlap demonstrates the ability of SPOT-Seq to go beyond homology-based inference to uncover novel RBPs.
Disease pathways associated with predicted RBPs
Validation of predicted novel RBPs provides incentive for analyzing their relevance to disease using known disease pathways of Kyoto Encyclopedia of Genes and Genomes (KEGG) database. 24 The KEGG database classified diseases into 11 types: cancer, immune system diseases, nervous system diseases, cardiovascular diseases, digestive diseases, urinary and reproductive diseases, musculoskeletal and skin diseases, respiratory diseases, congenital disorder of metabolism, and other congenital disorders. These diseases correspond to 176 pathways and 4602 proteins. Among these, 337 are annotated RBPs. One hundred fifty-one (44.8%) of the annotated RBPs are predicted by SPOT-Seq, consistent with the overall sensitivity of 42.6%. In addition to recover known RBPs, SPOT-Seq also predicted 284 novel RBPs. The overall fraction of RBPs, both predicted and annotated, in all proteins involved in disease pathways is about 13%, slightly lower than 18% for all proteins in the human genome. Table V lists the number of annotated and predicted RBPs for the 11 disease pathways. These newly predicted RBPs in disease pathways should be useful for understanding disease mechanisms and generating new hypotheses for experimental testing.
For example, there are six diseases such as Charcot-Marie-Tooth disease, progressive myoclonic epilepsy, and pontocerebellar hypoplasia involving in the aminoacyl-tRNA biosynthesis pathway. Eleven annotated RBPs are involved in this pathway, and seven of them were also predicted as RBPs by SPOT-Seq. In addition, SPOT-Seq discovered 18 novel RBPs. Most of the predicted novel RBPs (13/18 5 72%) used templates that bind with tRNA. Predicted binding with tRNA provide additional supports for our predicted novel RBPs.
DISCUSSION
In this study, a new method for RBP prediction based on known RBP complex structures was applied to human genome. The method uncovered 2418 proteins that were not previously annotated as RBPs in the GO database. About half of these predicted novel RBPs were annotated as ORFs that lack GO annotations of molecular functions (908) or have only GO root ID (247). Importantly, 284 of these predicted novel RBPs are linked to disease pathways (Table V) . Partial validation of this prediction tool includes 12% of these predicted All proteins: all human proteins in the specific GO ID; A: annotated RBPs; A\P predicted and annotated RBPs; P-A\P predicted but not annotated, novel RBPs; A1P-A\P: annotated plus predicted novel RBPs. A\P: predicted and annotated RBPs; P-A\P: predicted but not annotated, novel RBPs novel proteins (291) that have been identified in a recently study to bind mRNAs in living HeLa cells. 19 The consistent sensitivity (42.6% for annotated RBPs in human genome and 43.6% for mRBPs in HeLa Cells) demonstrates the robustness of SPOT-Seq in making highly accurate prediction of RBPs. Among all predicted RBPs, 80.5% have unknown functions or are annotated with functions other than RNA binding. This suggests that many more RBPs exist than those that are currently annotated. If we combine predicted RBPs with annotated RBPs and assume that majority of predicted and annotated RBPs are true, these RBPs would consist of 18% [(1848 1 570 1 1217)/20,270] of all genes. With the sensitivity of SPOT-Seq being about 43%, the actual number of RBPs is likely to exceed 18% even if when errors were taken into account. The potentially large number of RBPs highlights the scope and significance of the protein-RNA interaction network.
Most of the RBPs predicted here have functions other than RNA-binding. This so-called moonlighting capability of RBPs is consistent with experimental screens of yeast and human proteins. It was found that novel RBPs uncovered in screens often have enzymatic activities as well as RNA-binding architectures. 19 Thus, RBPs that moonlight in other functions is likely to be more common than previously appreciated. In particular, 39% of predicted moonlighting proteins are related to DNAbinding. This is not caused by inability of SPOT-Seq to distinguish RNA-from DNA-binding. In fact, the application of SPOT-seq to 250 DNA-binding proteins did not yield any false positive prediction of RBPs. 16 Thus, many proteins can interact with both RNA and DNA.
To prevent potential false positive prediction, we have excluded those predicted RBPs that are transmembrane proteins. This is because our template proteins are all globular proteins. Current implementation, however, requires a separate prediction of transmembrane proteins and manual comparison. In a future version, we hope to incorporate a transmembrane filter directly inside of SPOT-seq. However, excluding predicted transmembrane regions could lead to removal of some true positive predictions because the accuracy for prediction of transmembrane proteins is 88%. 23 We used the transmembrane filter in order to further improve the precision of our RBP prediction at a minor cost of fewer predictions.
A surprising result from our template-based technique is that many predicted RBPs used the templates from 60S ribosomal proteins, especially L3 (PDB ID 3o58). This is true for both predicted novel and annotated RBPs. We are confident about these predictions because our benchmark test indicates the accuracy of prediction based on 3o58 is the same as that based on other templates. More importantly, 87 novel RBPs based on 3o58 templates are validated as mRBPs. 19 The popularity of L3 and other ribosomal protein in predicting RBPs may have its origin in ribosomal proteins being ancient in the tree of life and the potential amplification of genes associated with translation.
To demonstrate the significance of predicted novel RBPs, we use the serine-protein kinase ATM as an example. ATM was matched to the complex structure between pre-microRNA and chain A of PDB structure 3a6p (exportin-5) by SPOT-Seq despite that the e-value given by PSI-BLAST is 100 (i.e., no homology-inferred function between ATM and exportin-5). Serine-protein kinase ATM is known for DNA-damage induced protein phosphorylation 25 and DNA binding. 26 There is no direct experimental evidence for its binding with RNA. However, a recent paper by Zhang et al. 27 found that the ATM kinase is involved in enhancing binding between KH-type splicing regulatory protein and pre-microRNA. The ATM kinase was also found to regulate the interaction between mRNA and HuR 28 and nuclear export of pre-microRNA. 29 Thus, the match between the predicted ATM structure with the binding region of pre-miRNA-binding exportin-5 is likely more than a simple coincidence.
One caveat of the SPOT-Seq method is its reliance on known protein-RNA complex structures as templates for predicting complex structures. That is, if no matching template is found, the query protein will be predicted as non-RBPs. An ab initio structure prediction technique to make structure prediction was not used because the accuracy of predicted structures by template-free techniques is not yet reliable. 30 The limited number of available templates of protein-RNA complex structures contributes to the sensitivity of our prediction to be 40%. That is, there are a significant number of false negatives. In addition to limited number of templates, inaccurately predicted binding regions due to rigid-body assumption in structural modeling could lead to steric clashes that prevent prediction of high binding affinity and thus lead to a false negative prediction.
In future, as more protein-RNA complex structures are solved, SPOT-Seq should improve the recovery of known RBPs and uncovering novel ones. Furthermore, it should be possible to increase the sensitivity of SPOT-seq by combing it with other sequence-and structure-based approaches. [8] [9] [10] [11] [12] [13] [14] [15] These analyses are in progress, but the ability to double the number of annotated RBPs with SPOT-Seq should generate hypotheses that will impact protein structure/function with relevance to human disease pathways.
